Phase II Study of High-Dose Cyclophosphamide in Patients With Refractory Pemphigus
NCT00010413 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 35
Last updated 2008-10-02
Summary
OBJECTIVES:
I. Determine the response rate and 1-year event-free survival of patients with refractory pemphigus treated with high-dose cyclophosphamide.
Conditions
- Pemphigus
Interventions
- DRUG
- DRUG
Sponsors & Collaborators
- lead OTHER
Principal Investigators
-
Grant J. Anhalt · Johns Hopkins University
Study Design
- Purpose
- TREATMENT
Eligibility
- Min Age
- 18 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 1999-04-30
- Primary Completion
- 2007-08-31
Countries
- United States
Study Locations
More Related Trials
-
Phase II Study of Oral Panobinostat in Adult Participants With Relapsed/Refractory Classical Hodgkin's Lymphoma
NCT00742027 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma
NCT00798096 ·Status: COMPLETED ·Phase: PHASE2
-
Dose-Escalation Trial of Carfilzomib With and Without Romidepsin in Cutaneous T-Cell Lymphoma
NCT01738594 ·Status: TERMINATED ·Phase: PHASE1
-
Long-Term Follow-up Study for Non-Hodgkin's Lymphoma Patients Who Received Study Treatment (Plerixafor or Placebo) in the AMD3100-3101 Study (NCT00103610).
NCT00741325 ·Status: COMPLETED
-
Zanubrutinib Plus GCVP (Obinutuzumab, Cyclophosphamide, Vindesine, Prednisolone) in Previously Untreated Follicular Lymphoma
NCT06918015 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Palifosfamide in Treating Patients With Recurrent Germ Cell Tumors
NCT01808534 ·Status: TERMINATED ·Phase: PHASE2
-
Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma
NCT07164469 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies
NCT06191887 ·Status: RECRUITING ·Phase: PHASE1
-
Mobilization of Stem Cells With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma Patients
NCT00103610 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Pharmacokinetic Study of IMM0306 in Patients With Refractory or Relapsed CD20-positive B-cell Non-Hodgkin's Lymphoma (B-NHL)
NCT04746131 ·Status: SUSPENDED ·Phase: PHASE1
-
Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma
NCT02481310 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Dasatinib in Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT00550615 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Evaluation of the Combination of Romidepsin and Carfilzomib in Relapsed/Refractory Peripheral T Cell Lymphoma Patients
NCT03141203 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma
NCT07283679 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Phase II Study of MDX-060 in Subjects With Relapsed or Refractory Hodgkin's Disease
NCT00284804 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Motexafin Gadolinium for the Treatment of Non-Hodgkin's Lymphoma
NCT00086034 ·Status: COMPLETED ·Phase: PHASE2
-
Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas
NCT02181218 ·Status: COMPLETED ·Phase: PHASE1
-
Ifosfamide, Teniposide, and Paclitaxel in Treating Patients With Relapsed Non-Hodgkin's Lymphoma
NCT00004916 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Rituximab, Combination Chemotherapy, Filgrastim (G-CSF), and Plerixafor in Treating Patients With Non-Hodgkin Lymphoma Undergoing Mobilization of Autologous Peripheral Blood Stem Cells
NCT01097057 ·Status: COMPLETED ·Phase: PHASE2
-
Cyclosporine in Treating Patients With Recurrent or Refractory Angioimmunoblastic T-Cell Lymphoma
NCT00070291 ·Status: TERMINATED ·Phase: PHASE2
-
Ruxolitinib Phosphate to Treat Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma After Stem Cell Transplant
NCT01431209 ·Status: COMPLETED ·Phase: PHASE2
-
AMD3100 (Plerixafor) Added to a Mobilizing Regimen of Granulocyte-colony Stimulating Factor (G-CSF) to Increase the Number of Peripheral Blood Stem Cells (PBSCs) in Patients With Hodgkin's Disease
NCT00396201 ·Status: COMPLETED ·Phase: PHASE2
-
Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma
NCT01186458 ·Status: TERMINATED ·Phase: PHASE2
-
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Adult Participants With Advanced or Refractory Solid Tumors or Lymphoma
NCT01703481 ·Status: COMPLETED ·Phase: PHASE1
-
Ifosfamide/Carboplatin/Etoposide/Rituxan Followed by Zevalin in Relapsed/Refractory Intermediate Grade B-Cell Lymphoma
NCT00193505 ·Status: COMPLETED ·Phase: PHASE2